AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04788706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low level Laser Therapy and Low level Laser Therapy plus Russian electrical stimulation
Description: LLLT over three weeks followed by an eight-week receiving LLLT application combined with Russian electrical stimulation
Study NCT04788706 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser and Placebo Laser plus Russian electrical stimulation
Description: Placebo laser over three weeks followed by an eight-week receiving Placebo laser application combined with Russian electrical stimulation
Study NCT00973232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl)
Description: DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fasting conditions
Study NCT00973232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDS-06C (650 mg acetaminophen and 75 mg tramadol)
Description: DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fed conditions
Study NCT00973232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zaldiar®
Description: Zaldiar® (325 mg acetaminophen and 37.5 mg tramadol HCl): two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
Study NCT00973232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultracet®
Description: Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
Study NCT00973232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two tablets of DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl), multiple doses, under both fed and fasting conditions
Description: Two tablets of DDS-06C, twice daily at 12-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
Study NCT00973232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zaldiar®, multiple doses,(fed & fasting):
Description: Two tablets of Zaldiar®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
Study NCT00973232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultracet®, multiple doses, (fed & fasting)
Description: Two tablets of Ultracet®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
Study NCT01367990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: The occipital scalp zone at risk for alopecia will be identified. The norepinephrine treatment site will be randomized to receive consistent treatment of one half of the scalp risk zone. Approximately 1.6 mL of a 400 mM norepinephrine solution will be applied topically to the norepinephrine site approximately 20 minutes prior to each radiation treatment, and placebo will be applied to the contralateral side (30-35 treatments).
Study NCT02186418 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ARU-1801
Description: Autologous CD34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector~* Subjects with sickle cell anemia will undergo hematopoietic stem cell procurement by bone marrow harvest or apheresis after mobilization with plerixafor~* Reduced intensity chemotherapy conditioning with single dose melphalan will be used to facilitate engraftment of ex-vivo transduced cells.
Study NCT01237197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide 5 micrograms (mcg) twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study.
Study NCT01237197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exenatide
Description: Exenatide 5 micrograms (mcg) twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study.
Study NCT01237197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were randomized to a placebo injection for the first three months, then given open-label Exenatide for the remaining three months (Initiated at 5 mcg, twice per day, delivered by subcutaneous injection. After 1 month, exenatide was uptitrated to 10 mcg, twice per day for the remaining 2 months of the drug treatment phase).
Study NCT00026169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study NCT00026169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00026169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04282408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scoliosis back brace
Description: The patients will use the traditional brace, if not already in use, for 2 weeks and then they will wear a 3D printed back brace for the following 2 weeks. Both the braces will be worn for the amount of hours per day prescribed by the physician.
Study NCT02105181 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Placement of a FCMS in the biliary tract of the patients
Description: During an ERCP procedure, a fully covered biliary metal stent (FCMS) is placed across a benign biliary stricture
Study NCT00909298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP889
Description: 300 mg
Study NCT00909298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02198118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Domiciliary exercises for the upper limbs
Description: Study group (SG) instructed to perform domiciliary exercises for the upper limbs.
Study NCT02490865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60
Description: RNS60, 4 ml dose nebulized twice daily
Study NCT02490865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal Saline, 4 ml dose nebulized twice daily
Study NCT00983658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: huMAb OX40L
Description: Intravenous repeating dose
Study NCT00983658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose
Study NCT03000660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax at one of four escalating doses
Study NCT03000660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20mg by mouth on days 1, 8, 15, and 22 of each cycle.
Study NCT03761368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning
Description: four cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of left upper - arm cuff
Study NCT03761368 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Remote Ischemic Preconditioning
Description: deflated cuff placed on the left arm for 40 min
Study NCT00749853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: follicle stimulating hormone
Description: Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations \<200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.
Study NCT00749853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: follicle stimulating hormone
Description: No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations \<200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
Study NCT02645019 — intervention group
Intervention type: DEVICE
Intervention: Cuffed ETT
Description: Cuffed endotracheal tube.
Study NCT02645019 — intervention group
Intervention type: DEVICE
Intervention: Cuffed LMA
Description: Cuffed laryngeal mask airway.
Study NCT02999204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Two different doses of Vitamin D3
Study NCT02999204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Two different doses of Vitamin D3
Study NCT00882817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: The intervention group will perform a 6 month pulmonary rehabilitation program which consists of training, patient education, nutrition counseling and psychosocial support. They will be evaluated with some tests for the study.
Study NCT01397968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YKP3089
Description: Capsule, dose to be titrated Tablet, dose to be titrated
Study NCT01397968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule Placebo tablet
Study NCT02873351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa-levodopa 25-100 mg
Description: included in arm description
Study NCT02873351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for carbidopa-levodopa 25-100 mg
Description: included in arm description
Study NCT02162199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1450
Description: Single sentinel dosing of 40 mg per unit capsules is planned to escalate from 80 mg to 160, 320, 480, 640 and 800 mg, per respective dosing group. Doses may be modified based on review of available safety and pharmacokinetic (PK) data.
Study NCT02162199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching single sentinel dosing of placebo capsules is planned to escalate from 2 capsules to 4, 8, 12, 16 and 20 capsules, per respective dosing group. The number of capsules will match those delivering Debio 1450 for the group, as those doses may be modified based on review of available safety and pharmacokinetic (PK) data.
Study NCT01237769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 2200 IU/day
Study NCT01237769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle advice
Description: Diet and exercise
Study NCT02905890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethisterone enantate
Description: Noristerat® 200mg, solution for intramuscular injection given every 8 weeks
Study NCT02905890 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Condoms
Description: Latex male condoms
Study NCT02905890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Condoms
Description: Latex male condoms
Study NCT02515721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pCLE-TB
Description: Patients will receive white-light endoscopic imaging, followed by probe-based Confocal Laser Endomicroscopy scanning on suspected lesions and 5 standardized locations. Then targeted Biopsies will be performed on locations with intestinal metaplasia, intraepithelial neoplasia, and carcinoma.
Study NCT02515721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual chromoendoscopy-TB
Description: Patients will receive virtual chromoendoscopy using iScan. Standard biopsies will be performed on all suspected lesions and standardized loctaions.
Study NCT02340364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education + Patient Navigation
Description: 208 patients randomized to self-care Education+ Patient Navigation-delivered self-care plan.
Study NCT02340364 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-care Education
Description: 208 patients randomized to self-care education alone.
Study NCT02738385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
Study NCT02738385 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Interval Training
Description: Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
Study NCT01173237 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use tracheal intubation for surfactant therapy
Description: Surfactant endotracheal administration after tracheal intubation
Study NCT01173237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of Proseal laryngeal mask airway for surfactant therapy
Description: Surfactant use by proseal laryngeal mask airway
Study NCT02433470 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation over the motor cortex
Study NCT02433470 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation over the motor cortex
Study NCT02264249 — intervention group
Intervention type: OTHER
Intervention: Esophagogastroduodenoscopy and colonoscopy split dose prep
Description: Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive the Split dose colonoscopy prep~split dose colonoscopy preparation- ½ evening before and ½ early AM (4L volume or 2L volume bowel preparation)
Study NCT02264249 — intervention group
Intervention type: OTHER
Intervention: Esophagogastroduodenoscopy and colonoscopy Evening before colonoscopy prep
Description: Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive Evening before (4L, 2L or miralax bowel preparation)
Study NCT02264249 — intervention group
Intervention type: OTHER
Intervention: Esophagogastroduodenoscopy and colonoscopy Same day prep colonoscopy preparation
Description: Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive Same day prep (4L volume or 2L volume or Miralax bowel preparation)
Study NCT02773810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Family Planning Services
Description: Women who agree to enrollment will undergo our intervention, which will include an educational intervention and free on-site provision of all reversible contraceptive options, including LARC. This educational 5 intervention will be a one-on-one educational session on all available methods of contraception, with an emphasis on the safety and efficacy of long-acting reversible contraception (LARC) and the importance of planning a pregnancy in women with medical conditions requiring anticoagulation. A provider (clinic officer, nurse or physician) trained in family planning counseling and provision will provide all counseling and discussions in Kiswahili. Women will then be offered free, on-site provision of whichever contraceptive method they choose by a trained provider.
Study NCT02831972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG120
Study NCT02831972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Study NCT04494802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lower pressure
Description: During the operation, cuff pressure of LMA flexible is maintained to 30cmH2O
Study NCT04494802 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: higher pressure
Description: During the operation, cuff pressure of LMA flexible is maintained to 50cmH2O
Study NCT01424072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auriculotherapy by needles
Description: The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
Study NCT01424072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auriculotherapy by seeds
Description: We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
Study NCT01193504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pred Forte
Description: Pred Forte BID for 4 weeks postop
Study NCT01193504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotemax
Description: Lotemax BID for 4 weeks postop.
Study NCT02876562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root coverage with collagen matrix
Description: the material used is a porcine derived native collagen matrix which serves an alternative to connective tissue graft. the material is 1.5 mm in thickness with a specific tissue surface to allow for cell migration and a fibrous outer layer. it has a resorption time of 6 months.
Study NCT02876562 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: root coverage with collagen matrix
Description: the material used is a porcine derived native collagen matrix which serves an alternative to connective tissue graft. the material is 1.5 mm in thickness with a specific tissue surface to allow for cell migration and a fibrous outer layer. it has a resorption time of 6 months.
Study NCT03009396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)
Description: For patients on ACTIVE or PLACEBO in the parent study (RHB-104-01), who were not in remission after 26 weeks
Study NCT02469311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine impregnated cloths
Description: Pre-operative use of Chlorhexidine cloths night before and morning of surgery
Study NCT02469311 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of care bathing with antibacterial soap and water
Description: Patients had standard pre-operative bathing with antibacterial soap and water the night before surgery.
Study NCT03959176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine
Description: 2 drops administered once in the left eye in both study arms
Study NCT03959176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropicamide
Description: 1 drop administered at two different times points in both eyes in both study arms
Study NCT03959176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine Ophthalmic Product
Description: 1 drop administered at two different time points in both eyes in both study arms
Study NCT00357682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg per day
Study NCT00357682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 80mg per day
Study NCT00357682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 300mg per day
Study NCT02970942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Once daily administration of semaglutide subcutaneously (s.c., under the skin) in three different doses (0.1 mg, 0.2 mg and 0.4 mg)
Study NCT02970942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily administration subcutaneously ( s.c., under the skin)
Study NCT04462627 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood group determination
Description: Determination of the blood group (ABO/LE)
Study NCT04462627 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Antibody titration
Description: Natural anti-A and anti-B antibody levels will be determined by a gel agglutination technique on the Biorad IH-500 automaton.
Study NCT04462627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Administration of a probiotic to healthy volunteers to determine if it increases the level of circulating natural anti-A and anti-B antibodies (Probactiol Plus (Metagenics)).
Study NCT04106752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Provide caffeine supplements with or without meal before exercise
Study NCT00689858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol, Ginkgo biloba and placebo
Description: dosing time
Study NCT00689858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol, Ginkgo biloba and placebo
Description: dosing time